EyePoint Pharmaceuticals Inc (EYPT)
11.84
-0.68
(-5.43%)
USD |
NASDAQ |
May 17, 16:00
11.83
-0.01
(-0.08%)
After-Hours: 20:00
EyePoint Pharmaceuticals Free Cash Flow (Quarterly): -32.36M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -32.36M |
December 31, 2023 | -23.99M |
September 30, 2023 | -16.92M |
June 30, 2023 | 56.63M |
March 31, 2023 | -17.32M |
December 31, 2022 | -13.17M |
September 30, 2022 | -14.33M |
June 30, 2022 | -19.34M |
March 31, 2022 | -20.31M |
December 31, 2021 | -16.67M |
September 30, 2021 | -7.918M |
June 30, 2021 | -10.57M |
March 31, 2021 | -15.10M |
December 31, 2020 | 5.703M |
September 30, 2020 | 1.008M |
June 30, 2020 | -5.147M |
March 31, 2020 | -16.36M |
December 31, 2019 | -11.49M |
September 30, 2019 | -14.77M |
June 30, 2019 | -17.13M |
March 31, 2019 | -13.52M |
September 30, 2018 | -11.88M |
June 30, 2018 | -6.126M |
March 31, 2018 | -4.819M |
December 31, 2017 | -5.038M |
Date | Value |
---|---|
September 30, 2017 | -6.032M |
June 30, 2017 | -4.578M |
March 31, 2017 | -4.559M |
December 31, 2016 | -5.014M |
September 30, 2016 | -6.486M |
June 30, 2016 | -4.393M |
March 31, 2016 | -4.333M |
December 31, 2015 | -3.199M |
September 30, 2015 | -4.504M |
June 30, 2015 | -3.096M |
March 31, 2015 | -3.997M |
December 31, 2014 | 21.23M |
September 30, 2014 | -4.00M |
June 30, 2014 | -2.958M |
March 31, 2014 | -1.906M |
December 31, 2013 | -2.27M |
September 30, 2013 | -3.785M |
June 30, 2013 | -3.399M |
March 31, 2013 | -1.975M |
December 31, 2012 | -1.814M |
September 30, 2012 | -1.625M |
June 30, 2012 | -1.844M |
March 31, 2012 | -2.162M |
December 31, 2011 | -2.519M |
September 30, 2011 | -2.881M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-32.36M
Minimum
Mar 2024
56.63M
Maximum
Jun 2023
-10.48M
Average
-14.94M
Median
Free Cash Flow (Quarterly) Benchmarks
Nanoviricides Inc | -1.988M |
Bio-Path Holdings Inc | -1.814M |
GlycoMimetics Inc | -10.52M |
Ocular Therapeutix Inc | -34.14M |
Aileron Therapeutics Inc | -10.39M |